Corporate Overview

Click to Download Executive Summary

De-Risked, High-Performance Technology Platform

Based in Massachusetts, the Company owns WAVEPulseTM Sterilization, a DNA/RNA modifying technology platform that is designed to completely sterilize bio-pathogens, super bugs, viruses, and other potentially lethal substances. This versatile and configurable platform uses a combination of controlled energies to reach a previously unattained Sterility Assurance Level (SAL) of 10-10, which significantly exceeds 10-4 to 10-6 levels currently available.

Prior to the Company’s formation, the core technology was commercialized and sold to neutralize lethal bio-pathogens, such as anthrax, sent via mail. This technology has also been designated under the Safety Act by the Science and Technology Directories of the Department of Homeland Security.

The Infectious World of Proteins (Prions), Bio-Pathogens, Biofilm, and Other Substances

Prions: Extremely stable infectious proteins that can cause Creutzfeldt-Jakob Disease and Bovine Spongiform Encephalopathy (BSE, also know as “mad cow” disease) which are incurable, degenerative and fatal diseases. There are no approved sterilization processes for prion contaminated medical equipment. Currently patients undergoing brain and other surgeries are at risk of prion infection from reprocessed surgical instruments.

Bio-Pathogens: These include MRSA (Methicillin-resistant Staphylococcus aureus), C. diff (Clostridium difficile), and CRE (carbapenem-resistant Enterobacteriaceae), a new Super Bug with a 50% patient mortality rate.

Biofilm: Collection of microorganisms and their protective matrix of proteins and polysaccharides. Biofilm colonies can adhere strongly to medical devices, resisting standard cleaning and serve as a source of post-surgical infection.

Large Addressable Market Opportunities

  • Sterilization Failures in Reprocessed Medical Equipment
    • Complex, minimally invasive devices
    • Rubber, plastic, metals, adhesives with complex articulating parts and long lumens
    • Reprocessing to OEM specifications for another use
    • More than 1.6 million endoscopy procedures annually
  • Destruction of Prions
    • Inability to destroy prions by existing processes
    • Patients undergoing more than 100,000 brain, spinal and eye surgeries are at risk of infection and death
  • WAVEPulse™ platform aligns with increasing cost reduction pressure under the Affordable Care Act

Intellectual Property Portfolio

The Company owns a strong and defensible intellectual property portfolio around WAVEPulseTM with issued patents.

Leadership Team

ONEighty C Technologies has an experienced leadership team, comprising Eric G. Walters, CEO and Co-Founder, and Michael G. Fritz, Director.   Their background encompasses operations, manufacturing, life sciences, startup business experience, strategic planning, technology development, finance, fundraising, high growth expertise, mergers and acquisitions and high exit multiples.

Key Milestones

Near-term key milestones for the Company’s proof-of-concept device, in partnership with a MA-based independent laboratory, are: (i) destruction of extremely stable proteins (e.g. prions); (ii) enabling sterility assurance in difficult-to-clean medical devices; (iii) limited efficacy of current low-temperature sterilization processes

Target Markets

Target markets include sterilization of medical equipment in hospitals, clinics, nursing homes, ambulatory surgical centers where there are unmet needs for consistent sterilization and terminal destruction of persistent pathogens, infectious agents and toxins.

Secondary to the medical marketplace, WAVEPulseTM can also be effective against the threat of hazardous bio-pathogens sent via the mail from a domestic or foreign terrorist, militant, activist, or disgruntled employee.

Top of Page